[Effect of High Council for Public Health on September 28th 2012 recommendation about antipapillomavirus vaccination on antipapillomavirus and trivalent or tetravalent DTP or DTCP co-vaccination in South Western France].
BACKGROUND
Antipapillomavirus vaccination is used to prevent genital infection by papilloma virus, responsible for a high morbidity. In France, the High Council for Public Health published on September 28th 2012 a new guideline decreasing the age of vaccination from 16 to between 11 to 14 allowing a joint vaccination with mandatory tetravalent or trivalent (against diphtheria, tetanus, pertussis and poliomyelitis Tdap-IPV or Td/IPV booster) vaccination. Our study aimed to assess if this guideline changed the rate of joint vaccinations.


METHODS
A descriptive before/after study was conducted on French health insurance reimbursement database at the regional level (Midi-Pyrénées area). The study period comprised 1 year before and 1 year after the publication of the new guideline. We assess the rate of co-vaccinations in these 2 periods and compared them by a Chi2test.


RESULTS
On the study period, 35,647 vaccines were reimbursed corresponding to 18,230 complete vaccinations. Concerning co-vaccinations, 3287 were reimbursed: 1406 (16.4%) before the publication of the guideline and 1881 (19.4%) after (P<0.01).


CONCLUSIONS
The new guideline was accompanied by a rapid increase in the rate of co-vaccinations. It did not diminish the rate of vaccination by antipapillomavirus.
Département universitaire de médecine générale, faculté de médecine de Toulouse III Paul-Sabatier, 133, route de Narbonne, 31062 Toulouse, France. Electronic address: jordan.birebent@dumg-toulouse.fr.
Jordan
J
Birebent
Département universitaire de médecine générale, faculté de médecine de Toulouse III Paul-Sabatier, 133, route de Narbonne, 31062 Toulouse, France.
Julie
J
Dupouy
Département universitaire de médecine générale, faculté de médecine de Toulouse III Paul-Sabatier, 133, route de Narbonne, 31062 Toulouse, France.
Céline
C
Roussel
Caisse nationale d'assurance maladie des travailleurs salariés, échelon local Midi-Pyrénées, 31015 Toulouse, France.
Robert
R
Bourrel
Département universitaire de médecine générale, faculté de médecine de Toulouse III Paul-Sabatier, 133, route de Narbonne, 31062 Toulouse, France.
Michel
M
Bismuth
Département universitaire de médecine générale, faculté de médecine de Toulouse III Paul-Sabatier, 133, route de Narbonne, 31062 Toulouse, France.
Stéphane
S
Oustric
D000293:Adolescent; D000328:Adult; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006801:Humans; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D014611:Vaccination / Q000706:statistics & numerical data*; D055815:Young Adult
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D053918:Papillomavirus Vaccines
Antipapillomavirus vaccine; Calendrier vaccinal; Couverture vaccinale; Coverage rate; Guideline; Recommandations; Vaccination antipapillomavirus; Vaccination schedule